News

Results Found (504)
December 11, 2008
At the forefront of innovation - Yissum at Biomed Magazine Dec. 2008 (Hebrew)

Inventions of Professors Citri, Mitrani and Baniyash receive fundings from Yissum's new Baby Seed Fund 

December 11, 2008
At the forefront of innovation - Yissum at Biomed Magazine Dec. 2008 (Hebrew)

Inventions of Professors Citri, Mitrani and Baniyash receive fundings from Yissum's new Baby Seed Fund 

December 11, 2008
Jerusalem- a capital of incentives for the Biomed Industry
December 10, 2008
No Auto Crash for Israel's Mobileye

Yissum Spin-off Mobileye, a developer of crash-detection technology, is doing just fine despite the dark cloud over the automotive industry

December 1, 2008
Nanotechnology: Now is the time to expose the next Intel, Microsoft and...

"We are experiencing a historic moment in time that offers the possibility to become key players in a new evolving industry." Says Dan Vilensky, Co-Chairman of the upcoming NanoIsrael 2009 Conference, that shall take place in Jerusalem on March...

November 28, 2008
Il campionato delle IDEE (Italian)

The Championship of ideas - Il Sole 24 Ore Milano

November 27, 2008
Matchmakers- The Success Story of Israeli Technology Transfer Companies

How do you transform research taking place in the ivory towers of academic institutes into viable products in the free market? 

November 16, 2008
Weizmann, Hebrew University top world ranking

'The Scientist' ranks Israeli academic institutions in first, second places in its annual search 'the best places to work in academia' outside the US

November 13, 2008
Hebrew U’s Yissum Licenses Inflammatory Disease Rx Tech to BioLineRx

Yissum, the technology transfer company of the Hebrew University of Jerusalem, has granted a worldwide exclusive license to BioLineRx to develop and commercialize BL-5040, a new antihormone for the treatment of inflammatory diseases.

November 9, 2008
Prof. Arie Belldegrun - A Zionist in California

Prof. Arie Belldegrun, Yissum's guest speaker at Biomed 2008, is convinced that the 21st century will focus on Biotech and calls upon all Israeli scientists to join hands in forming a flourishing Israeli Biotech industry.   

October 27, 2008
Yissum partner PharmAthene Initiates Phase I Clinical Trial of Nerve Agent...

PharmAthene Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that dosing of volunteers has begun in a U.S. Phase I clinical trial evaluating Protexia(R) for safety and...

October 8, 2008
Yissum offers new technologies that are worlds apart: computer pattern...

Rarely a week goes by when tech transfer giant Yissum, which handles IP commercialization for the Hebrew University of Jerusalem, doesn't announce a new innovation from its research labs. This week the company -- which claims to generate $1...